Clinicopathological and prognostic value of SNHG6 in cancers: a systematic review and a meta-analysis.
Cancer
Clinical outcome
LncRNA SNHG6
Meta-analysis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
22 Apr 2020
22 Apr 2020
Historique:
received:
10
01
2020
accepted:
12
04
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
13
1
2021
Statut:
epublish
Résumé
Dysregulation of the long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) has been found in multiple cancers. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers. A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. In total, 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56-2.52) with no heterogeneity (I High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.
Sections du résumé
BACKGROUND
BACKGROUND
Dysregulation of the long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) has been found in multiple cancers. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers.
METHODS
METHODS
A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage.
RESULTS
RESULTS
In total, 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56-2.52) with no heterogeneity (I
CONCLUSIONS
CONCLUSIONS
High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.
Identifiants
pubmed: 32321469
doi: 10.1186/s12885-020-06850-0
pii: 10.1186/s12885-020-06850-0
pmc: PMC7178593
doi:
Substances chimiques
Biomarkers, Tumor
0
RNA, Long Noncoding
0
long non-coding RNA SNHG6, human
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
343Subventions
Organisme : Zhejiang Chinese Medicine University
ID : 2018ZY03
Organisme : Zhejiang Chinese Medicine University
ID : 2018ZY04
Références
Arch Biochem Biophys. 2018 May 15;646:128-136
pubmed: 29608878
Biomed Pharmacother. 2018 Jun;102:452-457
pubmed: 29579705
Theranostics. 2019 Jul 9;9(18):5227-5245
pubmed: 31410212
Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8624-8629
pubmed: 30575902
Cancer Genomics Proteomics. 2017 May-Jun;14(3):143-160
pubmed: 28446530
Int J Biol Markers. 2018 May;33(2):148-155
pubmed: 29799357
J Exp Clin Cancer Res. 2019 Aug 14;38(1):356
pubmed: 31412903
Cell Cycle. 2019 Aug;18(16):1849-1867
pubmed: 31258024
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Theranostics. 2019 Jul 9;9(18):5298-5314
pubmed: 31410216
Cancer Manag Res. 2019 Jan 10;11:611-624
pubmed: 30666158
Pathol Res Pract. 2018 May;214(5):784-789
pubmed: 29506878
J Cell Biochem. 2019 Jan;120(1):357-367
pubmed: 30168179
Pathol Res Pract. 2019 Oct;215(10):152575
pubmed: 31387807
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Am J Transl Res. 2019 Feb 15;11(2):1084-1091
pubmed: 30899408
Cancer Manag Res. 2019 Jul 15;11:6581-6592
pubmed: 31410056
Biomed Pharmacother. 2019 Feb;110:294-301
pubmed: 30522015
Cancer Res. 2018 Jul 15;78(14):3849-3864
pubmed: 29844127
Cell Physiol Biochem. 2017;42(3):999-1012
pubmed: 28683446
J Cancer. 2019 Feb 26;10(6):1503-1510
pubmed: 31031860
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2670-2677
pubmed: 31257923
J Hematol Oncol. 2019 Jan 9;12(1):3
pubmed: 30626446
Front Genet. 2015 Apr 23;6:145
pubmed: 25954300
J Cell Mol Med. 2019 Aug;23(8):5025-5036
pubmed: 31119871
J Cancer. 2019 May 26;10(11):2386-2396
pubmed: 31258743
Int J Med Sci. 2019 Jan 1;16(1):51-59
pubmed: 30662328
Cancer Cell Int. 2019 Apr 3;19:82
pubmed: 30988663
Onco Targets Ther. 2018 Sep 12;11:5743-5752
pubmed: 30254467